Quality Comes First

          

APAC MARKETS

We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.

Discover more about Menarini Group

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.

Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.

Sharing your partnering idea

Leverage our omni-channel approach to grow your brand across Asia Pacific.

MARKETS

The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.

As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.

Our APAC Headquarters

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

Innovation & Research

Innovation & Research

Menarini Group engages in R&D to bridge an unmet global need for advanced research in healthcare biotechnology and diagnostics. We place strong emphasis on advancing highly specialised and scientifically valuable fields through close collaborations with academic and medical institutions to elevate the standard of healthcare not only in Asia, but globally.

While leveraging Singapore’s reputation for quality research and development (R&D) as an international biomedical hub that encompasses the entire innovation and manufacturing value chain, we also benefit from the country’s supportive operating environment and talent pool.

In 2021, Menarini Asia-Pacific, through A. Menarini Biomarkers Singapore Pte Ltd (MBS), signed a memorandum of understanding with the SingHealth Duke-NUS Maternal and Child Health Research Institute (MCHRI) to create a regional and international medical hub in Singapore for non-invasive diagnostics in prenatal, and targeted therapies for better clinical outcomes.